• Monday, March 29, 2021 @ 12:00 am

Critical phase III FORTRESS trial balixafortide in mBC remains on track to report results in 2021.
Up to CHF 24 mn grants awarded from CARB-X and CFF to support development of new antibiotic programs and inhaled murepavadin.
New CXCR4 lead compound announced and new “wild card” COVID-19 indication for balixafortide.

Key catalysts
Balixafortide pivotal phase III “FORTRESS” ORR results (Q2 2021)
New CXCR4 lead candidate (Q2 2021)
Balixafortide pivotal phase III “FORTRESS” PFS results (Q4 2021)

Go to the Polyphor Valuation Report

You may also be interested in